OTC Markets EXMKT - Delayed Quote USD

Adhera Therapeutics, Inc. (ATRX)

Compare
0.0024 0.0000 (0.00%)
At close: November 21 at 3:00 PM EST
Loading Chart for ATRX
DELL
  • Previous Close 0.0002
  • Open 0.0002
  • Bid 0.0080 x --
  • Ask 0.0130 x --
  • Day's Range 0.0002 - 0.0002
  • 52 Week Range 0.0001 - 0.0475
  • Volume 25,000
  • Avg. Volume 1,671
  • Market Cap (intraday) 17,330
  • Beta (5Y Monthly) -0.00
  • PE Ratio (TTM) --
  • EPS (TTM) -1.1700
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

adherathera.com

2

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ATRX

View More

Performance Overview: ATRX

Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ATRX
92.00%
S&P 500
25.15%

1-Year Return

ATRX
83.45%
S&P 500
31.54%

3-Year Return

ATRX
99.92%
S&P 500
27.06%

5-Year Return

ATRX
99.76%
S&P 500
92.34%

Compare To: ATRX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ATRX

View More

Valuation Measures

Annual
As of 11/21/2024
  • Market Cap

    17.33k

  • Enterprise Value

    10.81M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -532.88%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -4.61M

  • Diluted EPS (ttm)

    -1.1700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    32.39k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    563.75k

Research Analysis: ATRX

View More

Company Insights: ATRX

Research Reports: ATRX

View More

People Also Watch